Cargando…
Biosimilar, biobetter and next generation therapeutic antibodies
Formato: | Texto |
---|---|
Lenguaje: | English |
Publicado: |
Landes Bioscience
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3092613/ https://www.ncbi.nlm.nih.gov/pubmed/21285536 http://dx.doi.org/10.4161/mabs.3.2.14785 |
Ejemplares similares
-
From Biologics to Biosimilars and Biobetters – Democratization of High-end Therapeutics
por: Honavar, Santosh G
Publicado: (2021) -
Future of anti-VEGF: biosimilars and biobetters
por: Kapur, Monika, et al.
Publicado: (2022) -
Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters
por: Kim, HoUng, et al.
Publicado: (2021) -
An Omalizumab Biobetter Antibody With Improved Stability and Efficacy for the Treatment of Allergic Diseases
por: Liu, Peipei, et al.
Publicado: (2020) -
Therapeutic Monoclonal Antibodies and Emergence of Their Biosimilars
por: Jeddi-Tehrani, Mahmood
Publicado: (2018)